SEMAGLUTIDE

Information current as at: 1 April 2024

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Ozempic®
Pharmaceutical company:
Novo Nordisk Pharmaceuticals Pty. Ltd
Condition/indication:
(therapeutic use)
  • Type 2 diabetes mellitus (T2DM)
PBAC Submission type:
Change to listing (Major Submission)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
March 2021 PBAC meeting
Opportunity for consumer comment:
Open 23/12/2020 and close 10/02/2021 (see PBS Website)
PBAC meeting:
Held on 10/03/2021
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
07/04/2021
Lodgement of required documentation:
25/05/2021
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 02/06/2021
Status:
Finalised
Government processes:
Commenced on 15/06/2021
Medicine listed on the PBS:
01/09/2021 (see PBS schedule)

Case ID: a316

Page last updated: 04 April 2024

v0.9.17